Novo Nordisk
NVO
470 hedge funds and large institutions have $9.17B invested in Novo Nordisk in 2014 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 163 increasing their positions, 175 reducing their positions, and 27 closing their positions.
11% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 27
4% more capital invested
Capital invested by funds: $8.79B → $9.17B (+$386M)
0.22% more ownership
Funds ownership: 18.01% → 18.24% (+0.22%)
1% less funds holding
Funds holding: 473 → 470 (-3)
7% less repeat investments, than reductions
Existing positions increased: 163 | Existing positions reduced: 175
4% less funds holding in top 10
Funds holding in top 10: 26 → 25 (-1)
41% less call options, than puts
Call options by funds: $5.37M | Put options by funds: $9.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$112M |
| 2 |
O
OppenheimerFunds
New York
|
+$87.2M |
| 3 |
Jennison Associates
New York
|
+$58M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$23M |
| 5 |
HL
Harding Loevner
Bridgewater,
New Jersey
|
+$17.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lazard Asset Management
New York
|
-$40.5M |
| 2 |
Renaissance Technologies
New York
|
-$39M |
| 3 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$33.9M |
| 4 |
TIM
Thornburg Investment Management
Santa Fe,
New Mexico
|
-$24M |
| 5 |
WCM Investment Management
Laguna Beach,
California
|
-$16.7M |
NVO Hedge Fund Activity: Q3 2014 in Review
470 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q3 2014, worth a combined $9.17B — up 4.4% from $8.79B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new NVO positions and 27 closed out — a net gain of 3 holders — while 163 added to existing stakes and 175 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $112M. The largest seller was Lazard Asset Management, cutting an estimated $40.5M.
- 470 institutional investors held Novo Nordisk (NVO) as of Q3 2014, down from 473 in Q2 2014.
- Funds reported $9.17B of Novo Nordisk stock for Q3 2014, up 4.4% quarter-over-quarter.
- 30 funds opened new Novo Nordisk positions in Q3 2014 and 27 closed out, a net change of +3 holders.
- The largest Novo Nordisk buyer in Q3 2014 was Arrowstreet Capital, an estimated $112M added.
- The largest Novo Nordisk seller in Q3 2014 was Lazard Asset Management, an estimated $40.5M sold.
Based on aggregated 13F filings for Q3 2014.